Publications by authors named "U Ehmer"
Article Synopsis
- Immunotherapy combinations are the standard treatment for advanced hepatocellular carcinoma (HCC), with growing evidence supporting lenvatinib as a strong first-line option.
- A retrospective study analyzed 412 patients treated with either atezolizumab/bevacizumab (AZ/BV) or lenvatinib (LEN) across 18 European hospitals, revealing that those on AZ/BV experienced longer progression-free survival.
- Despite comparable survival rates between the two treatments overall, AZ/BV posed a higher risk of liver issues in patients with pre-existing liver function impairment, highlighting the need for careful patient monitoring.
Objective: Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with limited therapeutic options. mutations are among the most abundant genetic alterations in iCCA associated with poor clinical outcome and treatment response. Recent findings indicate that Poly(ADP-ribose)polymerase1 (PARP-1) is implicated in -driven cancers, but its exact role in cholangiocarcinogenesis remains undefined.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the efficacy and safety of first-line therapies for hepatocellular carcinoma (HCC), specifically comparing atezolizumab/bevacizumab (atezo/bev) and lenvatinib, focusing on bleeding and thromboembolic events.
- A total of 464 patients from seven centers in Germany and Austria were analyzed, revealing that bleeding and thromboembolic events occurred in similar rates for both treatments within 6 months.
- The findings suggest that safety concerns regarding bleeding and thromboembolic events might not significantly influence clinical decisions when selecting between atezo/bev and lenvatinib for HCC treatment.*